🚀 VC round data is live in beta, check it out!
MeiraGTx Valuation Multiples
Discover revenue and EBITDA valuation multiples for MeiraGTx and similar public comparables like Fulcrum Therapeutics, Contineum Therapeutics, Onconic Therapeutics, Cormedix and more.
MeiraGTx Overview
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Founded
2018
HQ
Employees
425
Website
Financials (LTM)
EV
$634M
MeiraGTx Financials
MeiraGTx reported last 12-month revenue of $46M and negative EBITDA of ($51M).
In the same LTM period, MeiraGTx generated $42M in gross profit, ($51M) in EBITDA losses, and had net loss of ($146M).
Revenue (LTM)
MeiraGTx P&L
In the most recent fiscal year, MeiraGTx reported revenue of $33M and EBITDA of ($122M).
MeiraGTx expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $46M | XXX | $33M | XXX | XXX | XXX |
| Gross Profit | $42M | XXX | $9M | XXX | XXX | XXX |
| Gross Margin | 91% | XXX | 29% | XXX | XXX | XXX |
| EBITDA | ($51M) | XXX | ($122M) | XXX | XXX | XXX |
| EBITDA Margin | (111%) | XXX | (366%) | XXX | XXX | XXX |
| EBIT Margin | (314%) | XXX | (493%) | XXX | XXX | XXX |
| Net Profit | ($146M) | XXX | ($148M) | XXX | XXX | XXX |
| Net Margin | (317%) | XXX | (444%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MeiraGTx Stock Performance
MeiraGTx has current market cap of $561M, and enterprise value of $634M.
Market Cap Evolution
MeiraGTx's stock price is $6.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $634M | $561M | 0.0% | XXX | XXX | XXX | $-1.84 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMeiraGTx Valuation Multiples
MeiraGTx trades at 13.7x EV/Revenue multiple, and (12.4x) EV/EBITDA.
EV / Revenue (LTM)
MeiraGTx Financial Valuation Multiples
As of March 21, 2026, MeiraGTx has market cap of $561M and EV of $634M.
Equity research analysts estimate MeiraGTx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MeiraGTx has a P/E ratio of (3.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $561M | XXX | $561M | XXX | XXX | XXX |
| EV (current) | $634M | XXX | $634M | XXX | XXX | XXX |
| EV/Revenue | 13.7x | XXX | 19.1x | XXX | XXX | XXX |
| EV/EBITDA | (12.4x) | XXX | (5.2x) | XXX | XXX | XXX |
| EV/EBIT | (4.4x) | XXX | (3.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | 66.8x | XXX | XXX | XXX |
| P/E | (3.8x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MeiraGTx Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MeiraGTx Margins & Growth Rates
MeiraGTx's revenue in the last 12 month grew by 184%.
MeiraGTx's revenue per employee in the last FY averaged $0.1M.
MeiraGTx's rule of 40 is 73% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MeiraGTx's rule of X is 348% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
MeiraGTx Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 184% | XXX | (26%) | XXX | XXX | XXX |
| EBITDA Margin | (111%) | XXX | (366%) | XXX | XXX | XXX |
| EBITDA Growth | (96%) | XXX | (47%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 73% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 348% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 112% | XXX | 163% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 285% | XXX | 359% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 522% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MeiraGTx Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Contineum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Onconic Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cormedix | XXX | XXX | XXX | XXX | XXX | XXX |
| Allogene Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MeiraGTx M&A Activity
MeiraGTx acquired XXX companies to date.
Last acquisition by MeiraGTx was on XXXXXXXX, XXXXX. MeiraGTx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MeiraGTx
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMeiraGTx Investment Activity
MeiraGTx invested in XXX companies to date.
MeiraGTx made its latest investment on XXXXXXXX, XXXXX. MeiraGTx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MeiraGTx
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MeiraGTx
| When was MeiraGTx founded? | MeiraGTx was founded in 2018. |
| Where is MeiraGTx headquartered? | MeiraGTx is headquartered in United Kingdom. |
| How many employees does MeiraGTx have? | As of today, MeiraGTx has over 425 employees. |
| Who is the CEO of MeiraGTx? | MeiraGTx's CEO is Alexandria Forbes. |
| Is MeiraGTx publicly listed? | Yes, MeiraGTx is a public company listed on Nasdaq. |
| What is the stock symbol of MeiraGTx? | MeiraGTx trades under MGTX ticker. |
| When did MeiraGTx go public? | MeiraGTx went public in 2018. |
| Who are competitors of MeiraGTx? | MeiraGTx main competitors are Fulcrum Therapeutics, Contineum Therapeutics, Onconic Therapeutics, Cormedix. |
| What is the current market cap of MeiraGTx? | MeiraGTx's current market cap is $561M. |
| What is the current revenue of MeiraGTx? | MeiraGTx's last 12 months revenue is $46M. |
| What is the current revenue growth of MeiraGTx? | MeiraGTx revenue growth (NTM/LTM) is 184%. |
| What is the current EV/Revenue multiple of MeiraGTx? | Current revenue multiple of MeiraGTx is 13.7x. |
| Is MeiraGTx profitable? | No, MeiraGTx is not profitable. |
| What is the current EBITDA of MeiraGTx? | MeiraGTx has negative EBITDA and is not profitable. |
| What is MeiraGTx's EBITDA margin? | MeiraGTx's last 12 months EBITDA margin is (111%). |
| What is the current EV/EBITDA multiple of MeiraGTx? | Current EBITDA multiple of MeiraGTx is (12.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.